Clinical Trials

Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Gilead Sciences announced that its GS-9674 has showed significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC) in a phase 2 trial.

Visterra begins phase 1 clinical study of monoclonal antibody VIS649

Clinical stage biotechnology firm Visterra has commenced a phase 1 clinical study of VIS649 in healthy volunteers.

4D pharma begins patient enrollment in Blautix IBS phase II study

UK-based 4D pharma has commenced patient enrollment for a phase 2 clinical trial to evaluate its single-strain live biotherapeutic candidate Blautix to treat Irritable Bowel Syndrome (IBS).

Glenmark plans to launch phase 1 trial in solid tumors for GBR 1342

Glenmark Pharmaceuticals has announced plans to launch a phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342.

Genkyotex’s liver disease drug GKT831 succeeds in phase 2 trial

Genkyotex’s NOX1/4 inhibitor GKT831 has succeeded in a phase 2 trial in primary biliary cholangitis (PBC), a type of liver disease, by meeting both primary and secondary interim efficacy endpoints.

BMS, Infinity to assess Opdivo-IPI-549 combo in urothelial cancer

A clinical trial collaboration has been formed to assess Bristol-Myers Squibb's (BMS) Opdivo in combination with Infinity Pharmaceuticals' IPI-549 in patients with advanced urothelial cancer.

Verona enrolls last patient in phase 2 trial for RPL554 in COPD

Verona Pharma has completed patient enrollment for a phase 2 trial for its nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic / long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).

ViiV Healthcare’s HIV-1 drug fostemsavir succeeds in phase 3 trial

ViiV Healthcare has reported positive results for its phase 3 BRIGHTE study of investigational fostemsavir at 48 weeks in heavily treatment-experienced (HTE) patients with HIV-1 infection.

Pfizer, Novartis partner to advance treatment of NASH

Pfizer has signed a non-exclusive clinical development agreement with Novartis to study one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH).